BC Week In Review | Jun 16, 2017
Clinical News

MD Anderson starts Phase I of evofosfamide plus Yervoy in solid tumors

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) said the University of Texas MD Anderson Cancer Center (Houston, Texas) started a Phase I trial to evaluate evofosfamide plus Yervoy ipilimumab in up to 69 patients with metastatic or locally...
BC Week In Review | Mar 24, 2017
Company News

Molecular Templates, Threshold deal

Molecular Templates is reverse-merging with Threshold. The combined entity would keep Molecular Templates' name, and intends to change its NASDAQ ticker to MTEM. Existing Molecular Templates shareholders will own 66% of the combined company, while...
BC Extra | Mar 17, 2017
Company News

Molecular Templates finds public path via Threshold

Molecular Templates Inc. (Austin, Texas) is reverse-merging with Threshold Pharmaceuticals Inc. (NASDAQ:THLD). The combined entity would keep Molecular Templates' name, and intends to change its NASDAQ ticker to MTEM. Existing Molecular Templates shareholders will own...
BC Week In Review | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat NSCLC and squamous cell carcinoma of the head and neck (SCCHN) or skin...
BC Week In Review | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and...
BC Week In Review | Oct 31, 2016
Company News

Caris Life Sciences, Threshold deal

Caris and Threshold partnered to develop a companion diagnostic for Threshold’s evofosfamide using Caris’ ADAPT biotargeting system. Evofosfamide is a hypoxia-activated cytotoxic 2-nitroimidazole prodrug of the DNA alkylator bromoisophosphoramide mustard (Br-IPM). Late last year, the...
BioCentury | Jan 4, 2016
Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
BC Week In Review | Jan 4, 2016
Company News

Threshold cancer news

Threshold will reduce headcount by about 66% to 20-25 to focus resources on two ongoing Phase II trials of tarloxotinib ( TH-4000 ) to treat non-small cell lung cancer (NSCLC) and squamous cell carcinomas of the head...
BC Week In Review | Dec 14, 2015
Clinical News

Evofosfamide: Development discontinued

Threshold and partner Merck discontinued development of evofosfamide to treat pancreatic cancer after the double-blind, international Phase III MAESTRO trial in 693 patients with previously untreated, locally advanced, unresectable or metastatic pancreatic adenocarcinoma showed that...
BC Week In Review | Dec 14, 2015
Clinical News

Evofosfamide: Development discontinued

Threshold and partner Merck discontinued development of evofosfamide to treat STS after the open-label, international Phase III TH-CR-406/SARC021 trial in 640 patients with locally advanced unresectable or metastatic STS previously untreated with chemotherapy showed that...
Items per page:
1 - 10 of 114